Business Description
TG Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US88322Q1085
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.89 | |||||
Equity-to-Asset | 4.09 | |||||
Debt-to-Equity | 0.07 | |||||
Debt-to-EBITDA | 2.05 | |||||
Interest Coverage | 4.01 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 4.55 | |||||
Beneish M-Score | 71.93 | |||||
WACC vs ROIC |
Growth Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 1063 | |||||
3-Year FCF Growth Rate | 51.5 | |||||
3-Year Book Growth Rate | -34 | |||||
Future 3-5Y Total Revenue Growth Rate | 43.16 |
Momentum Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 76.41 | |||||
9-Day RSI | 68.09 | |||||
14-Day RSI | 61.82 | |||||
6-1 Month Momentum % | 39.2 | |||||
12-1 Month Momentum % | -57.74 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Days Inventory | 637.9 | |||||
Days Sales Outstanding | 36.75 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.5 | |||||
Shareholder Yield % | -0.14 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 93.53 | |||||
Operating Margin % | 16.71 | |||||
Net Margin % | 14.24 | |||||
FCF Margin % | -10.56 | |||||
ROE % | 10.74 | |||||
ROA % | 14.18 | |||||
ROIC % | 57.24 | |||||
ROC (Joel Greenblatt) % | 133.35 | |||||
ROCE % | 22.27 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 75.02 | |||||
Forward PE Ratio | 68.91 | |||||
PE Ratio without NRI | 75.02 | |||||
PS Ratio | 8.71 | |||||
PB Ratio | 1.67 | |||||
Price-to-Tangible-Book | 1.67 | |||||
EV-to-EBIT | 45.53 | |||||
EV-to-EBITDA | 45.28 | |||||
EV-to-Revenue | 8.45 | |||||
EV-to-Forward-Revenue | 10.14 | |||||
EV-to-FCF | -77.8 | |||||
Price-to-Graham-Number | 2.36 | |||||
Earnings Yield (Greenblatt) % | 2.2 | |||||
FCF Yield % | -1.23 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
TG Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 268.922 | ||
EPS (TTM) (€) | 0.214 | ||
Beta | 2.81 | ||
Volatility % | 94.58 | ||
14-Day RSI | 61.82 | ||
14-Day ATR (€) | 0.504214 | ||
20-Day SMA (€) | 13.3323 | ||
12-1 Month Momentum % | -57.74 | ||
52-Week Range (€) | 6.182 - 31.95 | ||
Shares Outstanding (Mil) | 154.54 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
TG Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
TG Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
TG Therapeutics Inc Frequently Asked Questions
What is TG Therapeutics Inc(STU:NKB2)'s stock price today?
When is next earnings date of TG Therapeutics Inc(STU:NKB2)?
Does TG Therapeutics Inc(STU:NKB2) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |